P53 and mTOR signalling determine fitness selection through cell competition during early mouse embryonic development

Sarah Bowling1,2,3, Aida Di Gregorio1, Margarida Sancho1, Sara Pozzi4, Marieke Aarts2,3, Massimo Signore4, Michael D. Schneider1, Juan Pedro Martinez Barbera4, Jesús Gil2,3 & Tristan A. Rodríguez1

Ensuring the fitness of the pluripotent cells that will contribute to future development is important both for the integrity of the germline and for proper embryogenesis. Consequently, it is becoming increasingly apparent that pluripotent cells can compare their fitness levels and signal the elimination of those cells that are less fit than their neighbours. In mammals the nature of the pathways that communicate fitness remain largely unknown. Here we identify that in the early mouse embryo and upon exit from naive pluripotency, the confrontation of cells with different fitness levels leads to an inhibition of mTOR signalling in the less fit cell type, causing its elimination. We show that during this process, p53 acts upstream of mTOR and is required to repress its activity. Finally, we demonstrate that during normal development around 35% of cells are eliminated by this pathway, highlighting the importance of this mechanism for embryonic development.
From the earliest embryonic divisions until the death of the organism, cells are subjected to a remarkable array of pressures that will compromise their fitness. Cell competition is a quality control mechanism that allows the comparison of fitness levels between cells and results in the elimination of those which are viable but less fit than their neighbours. The process has been primarily studied in Drosophila, where it is thought to play beneficial roles in the optimisation of tissue fitness during embryonic development, the regulation of organ size and the maintenance of adult tissue homeostasis during ageing. In flies, cell competition can also be exploited by cancer cells to eliminate the surrounding wild-type tissue, both to make space for their expansion and fuel their transformation.

During the early stages of mammalian embryonic differentiation, a wide range of cellular changes take place, including a dramatic increase in the proliferation rate and a rewiring of the transcriptional, epigenetic, metabolic and signalling networks. The dimension of these changes and the requirement for their timing to be carefully orchestrated provides a significant potential for the emergence of aberrant cells that cannot perform these changes efficiently and need to be removed before specification of the germline. Consequently, the onset of gastrulation in mouse is accompanied by a wave of cell death as the epiblast becomes hypersensitive to death signals.

Cell competition has been suggested to be one of the quality control mechanisms that ensures fitness selection in the early mouse embryo. We have shown that during the onset of differentiation, cell competition eliminates defective or mis-patterned cells specifically when they are surrounded by fitter cells. Similarly, cells with lower levels of c-Myc than their neighbours or higher levels of p53 are also eliminated by cell competition in the mouse embryo. Recently in mouse, Myc-induced competition has been suggested as a mechanism to safeguard pluripotency, as the low c-Myc cells eliminated by cell competition were found to be less pluripotent than their high c-Myc counterparts. However, although differences in c-Myc and p53 are recognised by the cell competition machinery as differences in fitness levels, we do not know what pathways are activated in the mouse embryo downstream of these triggers specifically in a competitive context.

The mechanistic target of rapamycin (mTOR) pathway integrates a variety of extracellular and intracellular signals and functions to control cell growth and metabolism. The mTOR complex 1 (mTORC1), hereafter referred to as mTOR, drives anabolic metabolism in response to positive growth inputs but activates catabolic pathways during starvation. Here we report that mTOR signalling is a key effector of cell competition in the early mouse embryo, as loss of mTOR signalling is both required and sufficient for the elimination of defective cells in a competitive environment. We also find that the tumour suppressor p53 acts upstream of mTOR during this process, and that elevated p53 expression not only labels defective cells as less fit than their neighbours, but also is required for mTOR repression during cell competition. Together, these observations shed light on the pathways that regulate competitive fitness during early mouse development.

Results

mTOR is a readout of competition between pluripotent cells.

Here our aim is to identify the pathways that mediate fitness selection during early mouse embryogenesis, and specifically those that respond to relative fitness levels rather than eliminate cells with defects that directly affect their viability. For this we use two different cell models that carry defects that can emerge during early embryogenesis but are not intrinsically cell-lethal: mis-patterning and karyotypic abnormalities. The BMP signalling defective (Bmpria−/−) cells are mispatterned when surrounded by other defective cells, but are eliminated by cell competition when surrounded by wild-type cells. Similarly, tetraploid (4n) cells survive until very late in development or birth when the whole embryo is tetraploid, but are eliminated by apoptosis when in chimeras with wild-type cells. When referring to these two cell types, we collectively term them as defective or loser cells. To pursue the molecular mechanisms regulating their elimination when surrounded by wild-type cells we use a cell culture system where GFP-labelled defective embryonic stem cells (ESCs) are either co-cultured with wild-type cells or cultured as two separate homogeneous populations (separate culture). The phenotypes present in the co-culture condition, but not in the separate cultures, are deemed to be specific of cell competition. Cells are cultured in serum-free N2B27 media, as this induces differentiation and triggers cell competition. In these conditions, defective cells grow normally in separate culture but are efficiently eliminated from day 3 of co-culture (Fig. 1a).

To identify pathways involved in defective cell elimination, we used microarray profiling followed by Ingenuity Pathway Analysis (IPA), which identifies molecular interactions in omics data. Analysis of the transcriptome of wild-type and BMP-defective cells in separate and co-culture conditions revealed high activation Z-scores for mTOR and related pathways specifically in the co-culture condition (Supplementary Fig. 1A–C), suggesting that mTOR may regulate cell competition in the early mouse embryo. To test this hypothesis, we compared mTOR signalling in wild-type and defective cells in separate and co-culture conditions. We observed by immunofluorescence and flow cytometry analysis that ribosomal protein S6 (S6) phosphorylation, a key signalling readout of this pathway, was decreased in both BMP-defective and 4n cells specifically when they were co-cultured with wild-type cells (Fig. 1b–h and Supplementary Fig. 1D). This starkly contrasted with the robust levels of mTOR activation that control cells showed in separate and co-culture. Furthermore, when cell competition was inhibited by maintaining cells in the naive pluripotent state, we observed that mTOR activation in co-culture was similar in defective and wild-type cells (Supplementary Fig. 1E, F), indicating that the loss of mTOR signalling occurs specifically during competitive interactions. Thus, in two unrelated cell competition models, the confrontation with fitter cells leads defective cells to downregulate mTOR pathway activity.

Reduced mTOR signalling induces less-fit cell elimination.

mTOR plays many roles in the regulation of growth and is required for early post-implantation mouse development. We therefore asked if the decrease in mTOR activity observed in loser cells is the reason for their elimination. We have previously shown that caspase inhibition rescues loser cell elimination during cell competition. We found that preventing apoptosis also led to an accumulation of cells with low pS6 staining (Fig. 2a–c), suggesting these would otherwise be eliminated by cell competition. To test whether inhibition of the mTOR pathway is sufficient to induce cell death, we treated differentiating cells with the mTOR inhibitor rapamycin and assessed cell viability. Within 6 h, rapamycin markedly increased the activation of apoptotic markers and by 24 h it led to a 50% reduction in cell numbers (Fig. 2d–f). The cell counts could be rescued by caspase inhibition, indicating that decreasing mTOR activity during ESC differentiation induces death (Fig. 2d), a finding consistent with the requirement for mTOR signalling for post-implantation embryo survival. Our observations were not due to changes in mTORC2 pathway activation, as levels of pAKT2473, a direct phosphorylation downstream of mTOR, remained constant in both co-culture and separate culture conditions.
Fig. 1 Reduced levels of mTOR pathway activity in defective cells during cell competition. 

**a** Growth curves of wild-type and Bmpr1a−/− cells over 7 days in separate and co-culture. 

**b** Phospho-S6Ser240/244 levels in wild-type and Bmpr1a−/− cells cultured separately and together were assessed by immunofluorescence analysis and quantified (**c**). Scale bar = 200 μm. 

**d** Total (S6) and phospho-S6 (pS6) levels in wild-type and Bmpr1a−/− cultured separately and together were assessed by flow cytometry, and the median fluorescence of Bmpr1a−/−/wild-type cells was compared in separate and co-culture over the first three days in competition (**e**). 

**f** Levels of pS6Ser240/244 in wild-type and tetraploid (4n) cells after three days in competition were assessed by immunofluorescence. Scale bar = 50 μm. 

**g** Levels of pS6Ser240/244 levels in wild-type and 4n cells after three days in competition were assessed by flow cytometry and the median fluorescence of 4n/wild-type cells was compared in separate and co-culture at day three days of competition (**h**). n > 3; error bars denote standard error of the mean (SEM). **p < 0.01 and ***p < 0.005; unpaired, two-tailed t-test (**c, h** or ANOVA and Tukeys post-hoc test (**e**).
target of mTORC2, were not altered by rapamycin treatment (Fig. 2e). When naive pluripotent cells were treated with rapamycin no induction of apoptosis was observed (Fig. 2e, f), in agreement with the recent observations that in these cells low mTOR induces a diapause-like state. These results suggest that the loss of mTOR observed in defective cells during competition is directly causing their elimination.

**mTOR is required for less-fit cell elimination.** The above observations suggest that mTOR repression induces defective cell elimination, but we also wanted to address if restoring the activity of this pathway is sufficient to prevent this elimination. For this we targeted Tsc2 (tuberin), an inhibitor of the mTOR pathway, by CRISPR mutagenesis. Bmpr1a<sup>−/−</sup>;Tsc2<sup>−/−</sup> clones displayed a loss of TSC2 expression and increased phosphorylation of S6 (Supplementary Fig. 2A). Notably, this increase in mTOR activity induced by TSC2 inhibition completely rescued Bmpr1a<sup>−/−</sup> apoptotic cell elimination during cell competition (Fig. 3a, b). This was highlighted by the observations that Bmpr1a<sup>−/−</sup> cell numbers and apoptosis levels in co-culture were restored to those levels seen in these cells in separate culture (Fig. 3a). Importantly, accomplishing this rescue of Bmpr1a<sup>−/−</sup> cell elimination, we observed a change in the behaviour of the wild-type cells co-culture. We found that when wild-type cells were in a competitive environment with Bmpr1a<sup>−/−</sup>;Tsc2<sup>−/−</sup> cells, instead of growing exponentially they decreased in cell number (Fig. 3b). This indicates that complete abrogation of TSC2 function makes Bmpr1a<sup>−/−</sup> cells more competitive than wild-type cells. In contrast to this, although partial inhibition of Tsc2 using shRNAs or siRNAs also rescued Bmpr1a<sup>−/−</sup> cell elimination in co-culture, it did not affect wild-type cell numbers (Supplementary Fig. 2B-F and I), suggesting that the level of Tsc2 inhibition determines the competitive ability of a cell.

TSC2 has been described to regulate exit from pluripotency. To identify whether mTOR hyperactivation through Tsc2 knockdown was affecting competition through blocking cell differentiation, we analysed expression of pluripotency markers in Tsc2 knockdown cells. After three days in N2B27 no differences were observed compared to controls (Supplementary Fig. 2G–I) allowing us to exclude this possibility.

To assess whether mTOR is likewise functionally important in our tetraploid cell competition model we hyper-activated the pathway in 4n cells. We generated two 4n;Bmpr1a<sup>−/−</sup> clones displaying a loss of TSC2 expression and increased phosphorylation of S6 (Supplementary Fig. 3A). Notably, this increase in mTOR activity induced by TSC2 inhibition completely rescued Bmpr1a<sup>−/−</sup> apoptotic cell elimination during cell competition (Fig. 3a, b). This was highlighted by the observations that Bmpr1a<sup>−/−</sup> cell numbers and apoptosis levels in co-culture were restored to these levels seen in these cells in separate culture (Fig. 3a). Importantly, accomplishing this rescue of Bmpr1a<sup>−/−</sup> cell elimination, we observed a change in the behaviour of the wild-type cells co-culture. We found that when wild-type cells were in a competitive environment with Bmpr1a<sup>−/−</sup>;Tsc2<sup>−/−</sup> cells, instead of growing exponentially they decreased in cell number (Fig. 3b). This indicates that complete abrogation of TSC2 function makes Bmpr1a<sup>−/−</sup> cells more competitive than wild-type cells. In agreement with the recent observations that in these cells low mTOR induces a diapause-like state. These results suggest that the loss of mTOR observed in defective cells during competition is directly causing their elimination.
The observation that 4n-Tsc2 null cells can affect the growth of wild-type cells suggests that constitutive activation of mTOR signalling can make cells into super-competitors (i.e. capable of eliminating surrounding wild-type cells). To test this possibility in a diploid background, we deleted Tsc2 by CRISPR in wild-type cells and performed competition assays with unaltered wild-type cells. We selected two Tsc2−/− clones with absent levels of TSC2 and hyperactivation of mTOR (Supplementary Fig. 4A). While these Tsc2−/− cells were able to exit naive pluripotency and grew at similar rates to wild-type cells in separate culture (Supplementary Fig. 4B-C), they induced the apoptotic elimination of wild-type cells in co-culture, which showed a doubling in the proportion of cleaved caspase-3 positive cells at day 4 (Fig. 3e). Accompanying the elimination of wild-type cells in co-culture, the Tsc2−/− cells displayed increased growth (Fig. 3f), suggesting they were undergoing compensatory proliferation. These results indicate that mTOR is a key regulator of relative fitness levels, as not only does the loss of activity of this pathway lead to defective cell elimination, but also increasing mTOR activity is sufficient to trigger competition and transform cells into super-competitors.

p53 lies upstream of mTOR during defective cell elimination. We next looked for factors that could regulate mTOR during competition. For this we took a systematic approach and mined our IPA analysis of the transcriptional profiling of wild-type and defective cells for candidates. This study revealed p53, which is known to repress mTOR signalling28, as the gene with most enriched targets in defective cells (Supplementary Fig. 5A). Furthermore, in *Drosophila*, p53 is required for the metabolic reprogramming of winner cells during cell competition29 and in MDCK cells, hematopoietic stem cells and mouse embryos an elevation of p53 is sufficient to confer cells with a selective advantage.
disadvantage. We observed that expression of p53 and its target p21 were increased in both BMP-defective and 4n cells compared to wild-type cells in both separate and co-culture conditions (Fig. 4a–c, Supplementary Fig. 5B, C). In Bmpr1a−/− cells, this increase was not caused by double-strand DNA breaks, as very low levels of gamma-H2AX staining were observed in these cells (Supplementary Fig. 5D). These data suggest that elevated p53 expression is marking defective cells as potential loser cells.

To test if p53 lies upstream of mTOR, we did three things. First, we assessed whether p53 represses mTOR signalling in differentiating ESCs by performing a knockdown of p53 in wild-type cells using shRNAs and culturing these for three days in N2B27. We observed that inhibition of p53 resulted in an increase in mTOR pathway components pS6 and p4E-BP1 (Fig. 4d). Conversely, we treated wild-type cells with the p53 activator Nutlin-3a and found that increased expression of p53 leads to a repression of mTOR signalling activity (Fig. 4e, f). Neither treatment of cells with rapamycin nor deletion of Tsc2 by CRISPR affected p53 levels in Bmpr1a−/− cells (Supplementary Fig. 5E-F). Together, these data suggest that p53 activation can inhibit mTOR signalling but that the reverse is not the case.

We then analysed if inhibition of p53 can rescue mTOR levels and defective cell elimination during competition. We initially reduced p53 levels in Bmpr1a−/− or 4n cells co-cultured with wild-type cells using siRNAs. In both cases we observed a partial restoration of mTOR activation levels and a rescue of defective cell growth in co-culture (Supplementary Fig. 6A-F). To test if complete abrogation of p53 in defective cells led to a more dramatic rescue of their elimination, we generated Bmpr1a−/−; p53−/− cells using CRISPR (Supplementary Fig. 6G). We found that the deletion of p53 completely rescued both mTOR levels and the elimination of BMP-defective cells in competition with wild-type cells (Fig. 4g–i). These results indicate that p53 lies upstream of mTOR during defective cell elimination by cell competition.
P53 and mTOR signalling determine cell competition in vivo.

To address the in vivo significance of our observations, we first analysed tetraploid chimeras. Tetraploid embryos are viable until very late in gestation\(^{21-23}\), but we and others have previously shown that at 6.5 dpc 4n cells are efficiently eliminated in chimeras with 2n cells\(^{12,32}\). When we analysed levels of mTOR activity in 4n cells in chimeras at 5.0 dpc, just prior to the stage at which they are eliminated, we found that they display a loss of mTOR activity (Fig. 5a and Supplementary Fig. 7A). This indicated that defective cells also lose mTOR activity prior to their elimination in the embryo. We then tested if hyperactivation of the mTOR pathway is sufficient to rescue defective cell elimination in vivo. Injection of 4n-Tsc2\(^{-/-}\) ESCs into diploid embryos gave rise to high contribution chimeras that sustained high levels of pS6 at 9 dpc (Fig. 5c)\(^{12}\). Furthermore, in 43% of embryos these epiblast cells deformed the epithelial bilayer and overgrew into the pro-amniotic cavity (\(n=7\); Fig. 5b, d), suggesting that the persistence of 4n cells was disrupting embryonic development. In chimeras with diploid cells, 4n cells rarely survive past gastrulation\(^{32}\). However, we observed that 4n-Tsc2\(^{-/-}\) cells gave rise to highly chimeric embryos at 7.5 dpc and 9.0 dpc (Fig. 5d, e). In spite of their survival, at 9.0 dpc these embryos suffered a strong developmental delay and presented an abnormal epithelial organisation when compared to their littermates, either because of the negative effects of constitutive mTOR activation on development or because of the negative consequences that the persistence of tetraploid cells has on embryogenesis.

The above results indicated that repression of mTOR signalling leads to defective cell elimination during early mouse development and led us to investigate the frequency of this occurrence during normal development. For this we analysed pS6 levels in embryos cultured either in DMSO or with pan-caspase inhibitors for 16–18 h from 5.5 to 6.25 dpc. This treatment completely abolished TUNEL-positive apoptotic cells and led to a 35% increase in epiblast cell number (Fig. 6a–c). In cells, caspase inhibition results in an accumulation of Bmpr1a\(^{-/-}\) cells with low mTOR pathway activity (Fig. 2a–c). Similarly, we observed in vivo that while in control embryos few cells (\(\sim 3\%\)) showed loss of pS6\(^{5240/244}\), in embryos treated with the pan-caspase inhibitor there was a significant increase in the proportion of pS6\(^{5240/244}\), negative cells, with about 42% of cells showing low or no staining for this mTOR activation marker (Fig. 6d, e and Supplementary Fig. 8A). Analysis of total S6 levels revealed that those cells that

**Fig. 5** mTOR pathway repression is required for competition in vivo. **a** Chimeras generated by injecting 4n and 4n-Tsc2\(^{-/-}\) cells into wild-type blastocysts. Levels of pS6 were analysed at 5.0 dpc and 6.5 dpc, respectively. **b** Chimeras generated by injecting 4n (\(n=12\)) and 4n-Tsc2\(^{-/-}\) (\(n=4\)) cells into wild-type blastocysts. The white arrow indicates epiblast overgrowth of 4n-Tsc2\(^{-/-}\) cells in these chimeras. The white arrow also indicates epiblast overgrowth of 4n-Tsc2\(^{-/-}\) cells in these chimeras. Levels of cell death were assessed by cleaved caspase-3 staining at 6.5 dpc and quantified (c). **d** Chimeras generated by injecting 4n-Cas9-GFP and 4n-Tsc2\(^{-/-}\)-GFP cells into wild-type blastocysts. Embryos were analysed for GFP expression to determine contribution of 4n cells. **e** 4n-Tsc2\(^{-/-}\)-GFP cells were injected into wild-type blastocysts, embryos were collected at 9 dpc, and levels of 4n Tsc2\(^{-/-}\) GFP contribution were assessed by whole-mount immunofluorescence or by sectioning. Morphology of chimera is compared to wild-type control embryo. Scale bars are 50 μm for **a**, **b** and 100 μm for **d**, **e**. Error bars denote SEM (c). **p < 0.01; t-test.**
had down-regulated pS6 expression showed robust total levels of S6 protein in the epiblast (Fig. 6f, g and Supplementary Fig. 8B, C), confirming that the loss of mTOR signalling occurring in those cells fated for elimination is not due to a general decrease in protein expression. These results suggest that during early post-implantation development a rapid flux of cell competition eliminates around 35% of cells, and that this elimination likely occurs through repression of mTOR pathway activity.

We next analysed if p53 could also be upstream of mTOR in the embryo. At 5.5 dpc p53 expression is heterogeneous, with a...
small proportion of cells showing elevated p53 expression (Fig. 6h). Analysis of the relative p53 and pS6 levels in 5.5 dpc embryos failed to reveal any correlation between the expression of these factors in the unperturbed embryo (Supplementary Fig. 5D). One likely explanation for this is that p53 has a very short half-life and its expression oscillates, with apoptosis being induced only when protein levels are stabilised above a certain threshold. Furthermore, how quickly p53 levels increase in the cell also determines if apoptosis is induced or not. For these reasons, to obtain a rapid stabilisation of p53 and analyse how this affects mTOR activity, we have used the Mdm2 inhibitor Nutlin-3a. When 6.5 dpc embryos were cultured in the presence of Nutlin-3a for 6 h we observed a direct correlation at the single-cell level between p53 and pS6 levels (Fig. 6i, j). This suggests that in the embryo, sustained p53 expression is required to repress mTOR. These observations together with the findings that mutation of p53 in 4n cells allows these to give rise to very high chimeras that survive till birth, indicate that during early embryogenesis both p53 and mTOR signalling play key roles in defective cell elimination, and strongly suggest that p53 acts upstream of mTOR during this process.

Discussion

Cell competition is thought to act as a quality control mechanism and has primarily been studied in flies. More recently, fitness selection though cell competition has been shown in the early mammalian embryo at the onset of gastrulation. However, the mechanisms marking cells as less fit and those involved in loser cell elimination have remained obscure. Here we start to unravel these mechanisms with three key findings. First that two cell types with very different types of defects (mispatterned and karyotypically abnormal cells) are eliminated via mTOR-dependent cell competition. Second, in both genetic circuits, the karyotypically abnormal cells) are eliminated via mTOR-dependent cell competition. Second, in both genetic circuits, the karyotypically abnormal cells are eliminated via mTOR repression. First, it is possible that p53 elevation labels defective cells as losers, but when these cells are in a competitive environment a second unidentified factor becomes activated in these defective cells, and this mediates repression of mTOR and their elimination. Additionally it is possible that during competition, p53 changes in activity to repress mTOR and induce defective cell elimination. Distinguishing between these possibilities will help elucidate if the interaction between p53 and mTOR is direct or not.

Cell competition has been proposed to have roles from the elimination of defective cells in development to promoting the expansion of cancer cells during tumourigenesis. However, the roles of cell competition during mouse development remain unresolved. The recent observation that the low c-Myc cells eliminated by cell competition are of a lower pluripotency status (primed pluripotent), than their high c-Myc counterparts (that are naive pluripotent) has led to the interesting proposal that cell competition is acting to remove cells that exit naive pluripotency prematurely. However, it is important to define precisely at which developmental stage this removal is likely to be occurring. During early mouse embryogenesis, there are two waves of cell death that take place, one at the pre-implantation stage, at about 4.5 dpc and a second during early post-implantation development, at 6.5 dpc. At 4.5 dpc, epiblast cells are in the naive pluripotent state; therefore, it is plausible to argue that the wave of apoptosis occurring at this stage is removing cells that have acquired the primed pluripotent state precociously. In contrast to this, at 5.5 dpc in the early post-implantation embryo, all cells are uniformly primed pluripotent and then at 6.5 dpc and 7.5 dpc these cells initiate gastrulation in an asynchronous fashion. This makes it less likely that those cells dying at 6.5 pc are doing so because they have acquired a primed pluripotency status before their neighbours.

The scale of changes occurring during the onset of differentiation, including a doubling of the proliferation rate, means there is a significant potential for the emergence of defective cells. Therefore, an alternative possibility is that the cell elimination occurring at 6.5 dpc is because cell competition is acting as a quality control checkpoint to prevent these cells from contributing to the germline, that is specified around this time. One prime example of a cell type that could be eliminated by this mechanism is karyotypically abnormal cells. These are remarkably common in early mammalian development, for example in humans 50–80% of embryos have karyotypically abnormal cells at pre-implantation stages. However, karyotypic abnormalities are not necessarily per se prohibitive for early embryonic development, as even fully tetraploid embryos are viable until very late in gestation and they gastrulate at the same time as wild-type embryos. Here we show that cell competition eliminates these tetraploid cells in a mTOR-dependent manner at 6.5 dpc, just when the germline is being specified. The observation that

defective and tetraploid mouse ESCs, have a non-lethal increase in p53 independently of being in a competitive context suggests that a moderate increase in p53 occurs in response to a wide variety of stresses and acts as a less-fit signature. This signature does not directly affect viability, but instead labels cells as losers when placed in a competitive environment with wild-type cells, as we have found in the mouse embryo with BMPR-defective and tetraploid cells, or as others have observed through mutation of Mdm2

NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-04167-y

NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-04167-y
mutation of p53 allows tetraploid cells to give rise to high chimeras that survive till birth, strengthens the case for the involvement of p53-mTOR signalling in the elimination tetraploid cells. Therefore, together, these results suggest cell competition may be an important checkpoint for the removal of karyotypically abnormal cells acting before the germline forms to ensure its integrity.

A third possible role for cell competition during early mouse embryogenesis is in the regulation of embryo size. The mouse embryo is remarkably regulative and can compensate for a significant gain or loss of cells. For example, the embryo adjusts to a doubling in cell number at pre-implantation stages or a loss of up to 90% of cells at early post-implantation stages and regulates growth so that by organogenesis embryo size is similar to that of untreated controls. It is possible that by balancing proliferation and cell death, cell competition may coordinate the growth of the rapidly expanding early post-implantation mouse embryo, and in this way contribute to this regulative ability of growth of the rapidly expanding early post-implantation mouse embryo47 and in this way contribute to this regulative ability of the early mouse embryo. The fact that mTOR is a major metabolic regulator of the ability of pre-implantation embryos to regulate cell competition, the epithelial cells may be able to integrate nutrient and growth factor inputs and adjust cell numbers to ensure that the rapid acceleration of embryonic proliferation remains within specific parameters. The observation that treating pre-implantation embryos with insulin-like growth factor 1, that is, upstream of mTOR, leads to larger embryos by increasing inner cell mass cell numbers48, is tantalising evidence to suggest that cell competition may indeed play this role.

Tsc2 null mice die between 9.5 and 12.5 dpc. In contrast to this, p53 null mice survive until adult-hood51, but both p63 and p73 can compensate for its function during early post-implantation development. c-Myc is another important regulator of cell competition, and although c-Myc null mice die around 10.5 dpc, d-Myc can also compensate for c-Myc function during early mouse development. To help uncover the roles of cell competition it will be important to ascertain the levels of cell death in the above mutant strains, and if reduced, to establish the cell competition it will be important to ascertain the levels of cell death in the above mutant strains, and if reduced, to establish the identity of the cells that would normally have been eliminated. In parallel, it will also be interesting to test if mouse mutants for Tsc2, the p53 family or the Myc family can scale properly.

In conclusion, our work has uncovered that p53 regulation of mTOR is an important determinant of cellular fitness during early mammalian embryonic development. The fact that an increase or a decrease in expression of either of these signals induces defective cell elimination or super-competition just highlights this importance. It will be fascinating to uncover how conserved this pathway is in other mammalian tissues, as well as to understand if it plays any role in the fly.

Methods

Cell culture. Wild-type E14 cells were a gift from Prof. A. Smith; Bmp15a−/− cells and tetraploid cells were obtained from previously described sources. No cell lines used here are listed in the ICLAC and NCBI Biosample database of commonly misidentified cell lines. Cells were cultured at 37 °C and 5% CO2 in GMEM-BHK1 supplemented with 10% FCS, 2 mM glutamine, 1× MEM non-essential amino acids, 1 mM sodium pyruvate, 0.1 mM β-mercaptoethanol (all Thermo Fisher Scientific) and 100 units/ml leukaemia inhibitory factor (generated and tested in the lab). ES lines were maintained on gelatin-coated flasks and media was changed daily. Cell lines were routinely tested for mycoplasma contamination.

Details of rapamycin (Cayman Chemical), Nutlin-3a (BioVision) and caspase inhibitor (Z-VD-FMK, R&D Systems) treatments are outlined in figure legends.

Competition assay. Cells were seeded onto plates coated with fibronectin (Merck) at a concentration of 2.05 × 103 cells/cm2 either separately or mixed for co-cultures at a 50:50 ratio. The cells were cultured in N2B27 media (Neurobasal media, DMEM F12 media; 0.5 × B27 supplement; 0.5 × N2 supplement; 0.1 mM 2-mercaptoethanol; 2 mM glutamine; all Thermo Fisher Scientific) to allow for differentiation. At the indicated time-points, the cells were counted using ViCell Counter and Viability Analyser (Beckman Coulter) and proportions of each cell type in co-cultures were determined using LSR II Flow Cytometer (BD Bioscience). Sytox blue (Thermo Fisher Scientific) or propidium iodide (Sigma) was used to stain for dead cells.

Mice. All mice were maintained on a 10 hr–14 hr light–dark cycle and were maintained and treated in accordance with the Home Office’s Animals (Scientific Procedures) Act 1986. Wild-type mice analysed were on a CD1 out-bred genetic background. Noon of the day of finding a vaginal plug was designated 0.5 dpc. Embryo dissection was performed M2 media (Sigma). No distinction was made between male and female embryos during the analysis.

Chimeras. Embryos were harvested from F1 (C57BL/6 × CRA) or C57BL/6 × F1 crosses. 2.5 dpc embryos were flushed from euvivids in M2 (Sigma) and cultured in BlastAssist (Origin) under embry-embryo-tested media (Sigma) at 37 °C and 7% CO2 in air. ESCs (3–8) were injected via a laser-generated perforation in the zona pellucida using XYClone (Hamilton Thornc Biosciences).

Embryo culture. For caspase inhibitor experiments, embryos were dissected at 5.5 dpc, cultured overnight (18 h) at 37 °C and 5% CO2 in 200 μM pan-caspase inhibitor Z-VAD-FMK (R&D Systems) or the equivalent DMSO volume in poor N2B27 media (Neurobasal media; DMEM F12 media; 0.25 × B27 supplement; 0.25 × N-2 supplement; 0.1 mM 2-mercaptoethanol; 2 mM glutamine; all Thermo Fisher Scientific), and fixed as described. For Nutlin-3a experiments, embryos were dissected at 6.5 dpc, cultured in 10 or 20 μM Nutlin-3a (BioVision) or the equivalent DMSO volume for 6 h in poor N2B27 media, and fixed.

Immunofluorescence. Cells were fixed in 4% PFA for 10 min, permeabilised with 0.4% Triton X-100 for 5 min and blocked with 10% BSA (Sigma), 0.1% Triton X-100 for 1 h. Staining with primary antibodies (pS6Ser240/244 #5264, S6 #2317, p53 #2524, cleaved caspase-3 #9664, all Cell Signalling; and H2AX, Millipore 05-636; all 1:200 dilution) was performed overnight at 4 °C in 1% BSA, 0.1% Triton X-100. After three washes in PBS, secondary antibodies (Aкроm. Blocks were transferred to 1:200 dilution of Thermo Fisher Scientific; 1:500 dilution) and Hoechst (Thermo Fisher Scientific; 1:1000 dilution) were applied for 1 h. Coverslips were then mounted on glass slides using Vectashield (Vector Labs).

The embryos were fixed using 4% PFA in PBS −0.01%, Triton X-100 and 0.1% Triton X-100 for 1 h. Permeabilisation was performed with 0.5% Triton X-100 for 5 min, and embryos were blocked using 2% horse serum in PBS −0.1% Triton X-100 (PBT) for 45 min. Primary antibodies, as above, were incubated with embryos in blocking solution overnight at 4 °C. Following three washes in PBT, the embryos were incubated with secondary antibodies and Hoechst, as above, for 1 h at 4 °C. TUNEL staining was performed using Click-iT Plus TUNEL Assay (Thermo Fisher Scientific). All images were captured on a Zeiss LSM-780 confocal microscope.

Embryo cryosectioning was performed by soaking fixed (4% paraformaldehyde for 6 h at 4 °C) embryos first in 30% sucrose/PBS at 4 °C and then in 75% gelatin/15% sucrose/PBS at 37 °C before being transferred to room temperature to allow the embryos to mix with the sucrose/PBS. Embryos were fixed in 4% paraformaldehyde for 1 h, using 4% PFA for 10 min, and stored at −80 °C before sectioning. Sectioning was performed on a cryostat (Leica) using glass blades. GFP was detected using anti-GFP antibody #A-31851 (Thermo Fisher Scientific, 1:50 dilution).

In cells, the levels of cytoplasmic pS6 per field were quantified by measuring average fluorescence intensity in the two pixels surrounding cell nuclei, using Hoescht staining as a mask. Levels of nuclear p53 per field were quantified by measuring average fluorescence intensity in cell nuclei, using Hoescht staining as a mask. This was performed in ImageJ on single sections. In both cases, a minimum of three fields were quantified in each experiment.

For pS6 and p53 staining, a line was drawn manually across the nucleus and basal cytoplasm of each cell and the maximum fluorescence intensity across each line was measured. To define low pS6, a cut-off of 20 000 grey values (litter 1; n = 9), 12,000 grey values (litter 2; n = 9) or 10 000 grey values (litter 3; n = 10) was used to define low pS6. We adjusted the cutoff between litters owing to variability in mean fluorescence levels between independent experiments. A ratio cut-off of 0.3 was used to define the low pS6/S6 population. Example graphs showing the cut-off used are presented in Supplementary Fig. 8A-B. For cleaved caspase-3 quantification of tetraploid cells in embryos, cells positive or negative for cleaved caspase-3 were counted manually. In all cases, the analysis was performed in ImageJ on single sections.

Flow cytometry staining. Cells were detached from plates using accutase (Sigma) and fixed in 7.4% formaldehyde in N2B27 media for 10 min. 100, 540 cells were carried out using ice-cold methanol, and cells were blocked using 1% BSA. The primary antibody (pS6Ser240/244 #5264, cleaved caspase-3 #9664, both Cell Signalling; 1:200 dilution) was incubated with cells 1 h at room temperature. After washing, the secondary antibody was applied (Alexafluor-546/405, Thermo Fisher Scientific; 1:2000 dilution) and cleaved caspase-3 fluorescence staining was performed on live cells. The antibody was incubated with cells for 45 min at 4 °C and cells were washed in PBS prior to flow cytometry.
analysis. All flow cytometry was performed using a BD LSR II flow cytometer and analysed using FlowJo software (both BD Biosciences).

**Western blotting.** Cells lysates were collected using Laemmli buffer (BioRad) followed by transfer to PVDF membranes. Antibodies used are as follows: pS6 #2448, #5264, #2317, p38 #2524, #4E-BP1 #14480, #2855, total #4782 #5741, cleaved caspase-3 #9664, cleaved PARP #9544, pAKT #4060, #4061, TSC2 #4308, β-actin #4970; all from Cell Signaling Technology and used at 1:1000 dilutions. All uncropped western blots can be found in Supplementary Fig. 9.

**Molecular biology.** Total RNA was isolated using RNeasy (Qiagen) from three independent experiments. Labelling and hybridisation to the mouse Gene 1.0 ST Array system (Affymetrix), as well as data acquisition was performed by UCL. Genomic DNA was isolated using the Yeast Genomics at the Institute of Child Health. Normalisation and statistical analysis of the resulting array data was performed using GeneSpring software. Microarray data was also analysed by moderated t-test implemented by limma R package and a p-value cut-off of 0.05 was assigned for input into IPA.

Total cell mriRNA was extracted using RNeasy (Qiagen). cDNA was synthesised using Superscript III reverse transcriptase (Invitrogen), and SYBR Green Master Mix (Qiagen) was used for qPCR reaction. The following primers were used: Nanog F, TTCAAGAGGTCGCTACGTGATGC; Nanog R, TGCTTCTGCGGAAGG ACC; Ezh2 F, AACCGAAGTCTGCTCCAGAAC; Ezh2 R, GGTGGCTGAGGCATTCACT; Retin F, CAGATGGCAGTTTCTTCTG; Retin R, GACTCTACTT CCTGACGAAT; TGFβ F, ACCTATACCAAGAGTTCTCATC; Klf4 R, TGGGCT ACGTAAAGGTGAAGATAT) were cloned into a MSCV-miRE-IRES-GFP-puro vector to generate pCR3.1. All vectors were verified using Superscript III reverse transcriptase (Invitrogen), and SYBR Green Master Mix (Qiagen) was used for qPCR reaction. The following primers: pS6S240/244 #5264, S6 #2317, p53 #2524, p4E-BP1T37/46 #2855, total 4E-BP1 #14480, cleaved caspase-3 #9664, cleaved PARP #9544, pAKT #4061, p53 F, ACCAGAGGCATACAGGGACA.

**Statistical methods.** Statistical analysis was performed using GraphPad Prism software. Statistical methods used are indicated in the relevant figure legends. No randomisation or blinding was used in experiments. Sample sizes were selected based on the observed effects and listed in the figure legends.

**Data availability.** The raw data for wild-type and Bmp1rla mutant cells in separate culture and co-culture after three days in NR2B7 have been deposited in the GEO database with accession code GSE109494. The authors declare that all data supporting the findings of this study are available within the article and its supplementary information files or from the corresponding author upon reasonable request.

Received: 26 September 2017 Accepted: 6 April 2018

Published online: 02 May 2018

**References**

1. Moreno, E., Basler, K. & Morata, G. Cells compete for decapentaplegic survival factor to prevent apoptosis in Drosophila wing development. NATURE 416, 755–759 (2002).

2. Moreno, E. & Basler, K. dMyc transforms cells into super-competitors. Cell 117, 117–129 (2004).

3. de la Cova, C., Abril, M., Bellotta, P., Gallant, P. & Johnston, L. A. Drosophila myc regulates organ size by inducing cell competition. Cell 117, 107–116 (2004).

4. Merino, M. M. et al. Elimination of unitf cells maintains tissue health and prolongs lifespan. Cell 160, 461–476 (2015).

5. Eichenlaub, T., Cohen, S. M. & Herranz, H. Cell competition drives the formation of metastatic tumors in a Drosophila model of epithelial tumor formation. Curr. Biol. 26, 419–427 (2016).

6. Sujkerbuijk, S. J., Kolahgar, G., Kucinski, I. & Piddini, E. Cell competition drives the growth of intestinal adenomas in Drosophila. Curr. Biol. 26, 428–438 (2016).

7. Ballesteros-Arias, L., Saavedra, V. & Morata, G. Cell competition may function either as tumour-suppressing or as tumour-stimulating factor in Drosophila. Oncogene 33, 4377–4384 (2014).

8. Kojima, Y., Tam, O. H. & Tam, P. P. Timing of developmental events in the early mouse embryo. Semin. Cell Dev. Biol. 34, 65–75 (2014).

9. Pernaute, B. et al. MicroRNAs control the apoptotic threshold in primed pluripotent stem cells through regulation of BIM. Genes Dev. 28, 1873–1878 (2014).

10. Heyer, B. S., MacAuley, A., Behrendtson, O. & Werb, Z. Hypersensitivity to DNA damage leads to increased apoptosis during early mouse development. Dev. Cell 14, 19–30 (2013).

11. Sancho, M. et al. Competitive interactions eliminate unif embryonic stem cells at the onset of differentiation. Dev. Cell 26, 367–373 (2013).

12. Claveria, C., Giovinazzo, G., Sierra, R. & Torres, M. Myc-driven endogenous cell competition in the early mammalian embryo. Nature 500, 39–44 (2013).

13. Villa Del Campo, C., Claveria, C., Sierra, R. & Torres, M. Cell competition promotes phenotypically homoygous monocyte replacement in the Mammalian heart. Cell Rep. 8, 1741–1751 (2014).

14. Zhang, G. et al. p53 pathway is involved in cell competition during mouse embryogenesis. Proc. Natl Acad. Sci. USA 114, 498–503 (2017).

15. Diaz-Diaz, C. et al. Pluripotency surveillance by Myc-driven competitive elimination of differentiating cells. Dev. Cell 42, 585–599 (2017).

16. Laplante, M. & Sabatini, D. M. mTOR signaling in growth control and disease. Cell 149, 274–293 (2012).

17. Grabarek, J. R. et al. Differential plasticity of epiblast and primitive endoderm precursors within the ICM of the early mouse embryo. Development 139, 129–139 (2012).

18. van Echten-Arends, J. et al. Chromosomal mosaicism in human preimplantation embryos: a systematic review. Hum. Reprod. Update 17, 620–627 (2011).

19. Di-Gregorio, A. et al. BMP signalling inhibits premature neural differentiation in the mouse embryo. Development 134, 3359–3369 (2007).

20. Kaufman, M. H. Histochemical identification of primordial germ cells and differentiation of the gonads in homoygous tetraploid mouse embryos. J. Anat. 179, 169–181 (1991).

21. Kaufman, M. H. Postcranial morphological features of homoygous tetraploid mouse embryos. J. Anat. 180(Pt 3), 521–534 (1992).

22. Snow, M. H. Embryonic development of tetraploid mice during the second half of gestation. J. Embryol. Exp. Morphol. 34, 707–721 (1975).

23. Gangloff, V. G. et al. Disruption of the mouse mTOR gene leads to early postimplantation lethality and prohibits embryonic stem cell development. Mol. Cell. Biol. 24, 9508–9516 (2004).

24. Murakami, M. et al. mTOR is essential for growth and proliferation in early mouse embryos and embryonic stem cells. Mol. Cell. Biol. 24, 6710–6718 (2004).

25. Bulut-Karslioglu, A. et al. Inhibition of mTOR induces a caused pluripotent state. Nature 540, 119–123 (2016).

26. Betschinger, J. et al. Exit from pluripotency is gated by intracellular redistribution of the HILC transcription factor Tle3. Cell 153, 335–347 (2013).

27. Berkers, C., Maddocks, O. D., Cheung, E. C., Mor, I. & Vousden, K. H. Metabolic regulation by p53 family members. Annu. Rev. Biochem. 80, 1177–1198 (2011).

28. de la Cova, C. et al. Supercompetitor status of Drosophila M cells requires p53 as a fitness sensor to reprogram metabolism and promote viability. Cell. Metab. 19, 1–14 (2014).

29. Wagstaff, L. et al. Mechanical cell competition kills cells via induction of lethal p53 levels. Nat. Commun. 7, 11373 (2016).

30. Bondar, T. & Medzhitov, R. p53-mediated hematopoietic stem and progenitor cell competition. Cell Stem Cell 6, 309–320 (2010).

31. Eakin, G. S., Hadjantonakis, A. K., Papaioannou, V. E. & Behringer, R. R. Developmental potential and behavior of tetraploid cells in the mouse embryo. Development 128, 150–159 (2001).

32. Purvis, J. E. et al. p53 dynamics control cell fate. Science 336, 1440–1444 (2012).

33. Batchelor, E., Loewer, A., Mock, C. & Lahav, G. Stimulus-dependent dynamics of p53 in single cells. Mol. Syst. Biol. 7, 488 (2011).
35. Paek, A. L., Liu, J. C., Loewer, A., Forrester, W. C. & Lahav, G. Cell-to-cell variation in p53 dynamics leads to fractional killing. Cell 165, 631–642 (2016).
36. Hori, T. et al. p53 suppresses tetraploid development in mice. Sci. Rep. 5, 8907 (2015).
37. Hafezi, Y., Bosch, J. A. & Harisahran, I. K. Differences in levels of the transmembrane protein Crumbs can influence cell survival at clonal boundaries. Dev. Biol. 368, 358–369 (2012).
38. Wang, Q. et al. The p53 family coordinates Wnt and nodal inputs in embryonic erythroblast survival and hematopoietic stem cell function. Dev. Cell 35, 511–522 (2016).
39. Donehower, L. A. et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356, 215–221 (1992).
40. Wang, Q. et al. The p53 family coordinates Wnt and nodal inputs in mesendodermal differentiation of embryonic stem cells. Cell Stem Cell 20, 70–86 (2016).
41. Dubois, N. C. et al. Placental rescue reveals a sole requirement for c-Myc in embryonic erythoblast survival and hematopoietic stem cell function. Development 135, 2455–2465 (2008).
42. Scognamiglio, R. et al. Myc depletion induces a pluripotent dormant state mimicking diapause. Cell 164, 668–680 (2016).
43. Scognamiglio, R. et al. Myc depletion induces a pluripotent dormant state mimicking diapause. Cell 164, 668–680 (2016).
44. Scognamiglio, R. et al. Myc depletion induces a pluripotent dormant state mimicking diapause. Cell 164, 668–680 (2016).
45. Scognamiglio, R. et al. Myc depletion induces a pluripotent dormant state mimicking diapause. Cell 164, 668–680 (2016).
46. Scognamiglio, R. et al. Myc depletion induces a pluripotent dormant state mimicking diapause. Cell 164, 668–680 (2016).
47. Scognamiglio, R. et al. Myc depletion induces a pluripotent dormant state mimicking diapause. Cell 164, 668–680 (2016).
48. Scognamiglio, R. et al. Myc depletion induces a pluripotent dormant state mimicking diapause. Cell 164, 668–680 (2016).
49. Scognamiglio, R. et al. Myc depletion induces a pluripotent dormant state mimicking diapause. Cell 164, 668–680 (2016).
50. Scognamiglio, R. et al. Myc depletion induces a pluripotent dormant state mimicking diapause. Cell 164, 668–680 (2016).
51. Scognamiglio, R. et al. Myc depletion induces a pluripotent dormant state mimicking diapause. Cell 164, 668–680 (2016).
52. Scognamiglio, R. et al. Myc depletion induces a pluripotent dormant state mimicking diapause. Cell 164, 668–680 (2016).
53. Scognamiglio, R. et al. Myc depletion induces a pluripotent dormant state mimicking diapause. Cell 164, 668–680 (2016).
54. Scognamiglio, R. et al. Myc depletion induces a pluripotent dormant state mimicking diapause. Cell 164, 668–680 (2016).
55. Scognamiglio, R. et al. Myc depletion induces a pluripotent dormant state mimicking diapause. Cell 164, 668–680 (2016).
56. Scognamiglio, R. et al. Myc depletion induces a pluripotent dormant state mimicking diapause. Cell 164, 668–680 (2016).
57. Fu, C. & Ess, K. C. Conditional and domain-specific inactivation of the Tsc2 gene in neural progenitor cells. Genesis 51, 284–292 (2013).